SCHEMBL3229637

SCHEMBL3229637

Fc1ccc(N=C=S)c(F)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
ABCB11 O95342 1/20 0.36
NR3C1 P04150 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
ADRA2A P08913 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
ADRA2C P18825 1/20 0.36
MAOA P21397 1/20 0.36
DRD1 P21728 1/20 0.36
SLC6A4 P31645 1/20 0.36
HTR2B P41595 1/20 0.36
CCR2 P41597 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MIF P14174 1/20 0.34
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30940600 1.00 ALDH1A1 (0.36) ALDH1A1ABCB11NR3C1CYP1A2CYP3A4
SCHEMBL9694327 0.81 ABCB11 (0.33) ALDH1A1ABCB11NR3C1CYP1A2CYP3A4
SCHEMBL2768046 0.80 ALDH1A1 (0.48) ALDH1A1ABCB11NR3C1CYP1A2CYP3A4
SCHEMBL17650697 0.78 ABCB11 (0.34) ALDH1A1ABCB11NR3C1CYP1A2CYP3A4
SCHEMBL17650560 0.78 ALDH1A1 (0.37) ALDH1A1ABCB11NR3C1CYP1A2CYP3A4
SCHEMBL30438482 0.77 CYP3A4 (0.40) ALDH1A1CYP3A4HPGDTDP1CES2
SCHEMBL162877 0.77 CYP3A4 (0.40) ALDH1A1CYP3A4HPGDTDP1CES2
SCHEMBL22602688 0.77 APLNR (0.40) ALDH1A1ABCB11NR3C1CYP1A2CYP3A4
SCHEMBL10326019 0.74 GABRA1 (0.38) MIFP2RY6
SCHEMBL3287519 0.74 ABCB11 (0.34) ALDH1A1ABCB11NR3C1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160250175-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE JC (WUXI) COMPANY, INC. (CN) 2016-09-01 US claimed
EP-3034076-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE JC (Wuxi) COMPANY, Inc. (CN) 2016-06-22 EP claimed
CN-105267967-A Combined application of isothiocyanate-type compound and anti-cancer drug acting or affecting DNA WUXI JC PHARMACAUTICAL TECHNOLOGY INC 2016-01-27 CN claimed
CN-104415332-A Combined application between isothiocyanate-type compound and kinase inhibitor medicine in treatment of cancer WUXI JC PHARMACAUTICAL TECHNOLOGY INC 2015-03-18 CN claimed
CN-104117064-A Combined application of isothiocyanate compound and hormone medicine WUXI JC PHARMACAUTICAL TECHNOLOGY INC 2014-10-29 CN claimed
EP-3446689-B1 ISOTHIOCYANATE COMPOUND FOR USE IN THE TREATMENT OF HYPERBILIRUBINEMIA JC WUXI COMPANY INC (CN) 2025-01-08 EP disclosed
CN-113262218-B Use of isothiocyanate compounds 无锡杰西医药股份有限公司 2024-06-18 CN disclosed
US-11298334-B2 Use of isothiocyanate compounds JC (WUXI) COMPANY, INC. (CN) 2022-04-12 US disclosed
CN-113262218-A Application of isothiocyanate compounds 无锡杰西医药股份有限公司 2021-08-17 CN disclosed
CN-113181160-A Application of isothiocyanate compounds 无锡杰西医药股份有限公司 2021-07-30 CN disclosed
CN-104173272-B Sustained-release preparation of isothiocyanate compounds 无锡杰西医药股份有限公司 2021-07-06 CN disclosed
CN-109415602-B 2-cyanoacrylate-based adhesive composition 东亚合成株式会社 2021-05-25 CN disclosed
EP-0286089-B1 QUINOLINECARBOXYLIC ACID DERIVATIVES, A COMPOSITION COMPRISING THE SAME, PROCESS FOR PREPARING THE SAME, AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICAMENTS KANEBO, LTD. (JP) 1991-11-13 EP disclosed
US-5011831-A Bactericides NIPPON SHINYAKU CO. LTD. (JP) 1991-04-30 US disclosed
EP-0393538-A2 Thiazetoquinoline-3-Carboxylic acid derivative, method for preparation thereof, and a pharmaceutical composition comprising the same HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1990-10-24 EP disclosed
US-4853469-A BACTERICIDES KANEBO, LTD. (JP) 1989-08-01 US disclosed
CN-1033054-A Quinoline carboxylic acid derivative NIPPON SHINYAKU CO LTD (JP) 1989-05-24 CN disclosed
EP-0315827-A1 Derivatives of quinolinecarboxylic acid NIPPON SHINYAKU COMPANY, LIMITED (JP) 1989-05-17 EP disclosed
US-4808584-A Quinolinecarboxylic acid derivatives and antibacterial agent containing the same KANEBO, LTD. (JP) 1989-02-28 US disclosed
EP-0286089-A1 Quinolinecarboxylic acid derivatives, a composition comprising the same, process for preparing the same, and the use of the same for the manufacture of medicaments KANEBO, LTD. (JP) 1988-10-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160250175-A1 COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE CHUK, KIT, MKI67 ALDH1A1 2081/4885ABCB11 619/4885NR3C1 480/4885
US-11298334-B2 Use of isothiocyanate compounds LIPC, CETP, LCAT ALDH1A1 951/4885ABCB11 152/4885NR3C1 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.